Navigation Links
Independent publication supports the profile of CeNeS phase II,compound, CNS 5161

CAMBRIDGE, England, 4th May 2007 - CeNeS Pharmaceuticals plc (LSE: CEN), the Cambridge based biopharmaceutical company, notes the publication of an independent study in the respected scientific journal 'Synapse'* on its Phase II NMDA antagonist, CNS 5161. CeNeS is developing CNS 5161 as a potential treatment for neuropathic pain. The independent study builds on the work that CeNeS has already undertaken with CNS 5161.

In the study reported in 'Synapse', Dr Anat Biegon and her group at the Brookhaven National Laboratory, New York, USA, have studied a radioactively labelled version of CNS 5161. They have shown that CNS 5161 is a selective and high affinity NMDA receptor antagonist with preferential binding to the activated form of the receptor. The group also demonstrated that CNS 5161 penetrates the brain well and can be used to label selectively brain NMDA receptors in vivo. Dr Biegon proposes that a radioactive form of CNS 5161 may be used as an agent to monitor NMDA receptors in the human brain using Positron Emission Tomography ("PET") and notes that "the significance of a selective, validated radiopharmaceutical agent suitable for detecting widespread as well as highly localized changes in the NMDA receptor in the living brain cannot be exaggerated".

Data from Phase I and Phase IIa studies previously carried out by CeNeS have shown that CNS 5161 has analgesic properties in patients with neuropathic pain, but does not induce the severe psychotomimetic side-effects associated with other NMDA antagonists.

Neil Clark, Chief Executive of CeNeS, said:

"The data published in this paper supports and extends our original findings with CNS 5161. It has proved very difficult to develop a PET agent with the properties that make it possible to monitor NMDA receptor activation in the human brain. The profile of CNS 5161 as a selective, high affinity and brain-penetrating agent now make this a
'"/>




Page: 1 2 3

Related medicine technology :

1. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
2. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
3. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
4. Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent
5. Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies
6. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
7. CeNeS Pharmaceuticals Plc Announces Preliminary Results for The Year Ending 31 December 2006
8. CeNeS Pharmaceuticals plc: Update on Successful Phase III results announced on Lead Product M6G
9. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
10. Positive results from placebo-controlled phase IIa study in patients suffering from house dust mite allergy
11. Isotechnikas independent data monitoring committee conducts review of phase 2b kidney transplant trial
Post Your Comments:
(Date:5/22/2015)... Electrophysiologist Kevin Makati, M.D. with St. ... Boston, MA to speak about ... Society conference. These scientific sessions drew more than ... people and technology that propel their specialty forward. ... invasive cardiac operation that combines the expertise of ...
(Date:5/22/2015)... 2015 The North American dental lasers ... estimated to reach $90.7 million by 2019, at a CAGR ... the TOC of North America Dental Lasers Market for an ... various tables and figures. http://www.micromarketmonitor.com/market/north-america-dental-lasers-1771208223.html ... report.   Dental lasers are specifically used ...
(Date:5/22/2015)...  The U.S. Food and Drug Administration,s (FDA) ... biosimilar product approved in the United ... the contract manufacturing organization (CMO) industry, according to ... to the production of small-molecular drugs and lacks ... healthcare market research publisher,s report, Biopharmaceutical and ...
Breaking Medicine Technology:St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 2North America Dental Lasers Market is Expected to Reach $90.7 Million by 2019, at a CAGR of 9.2% From 2014 to 2019 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4
... Columbia Laboratories, Inc. (Nasdaq: CBRX ), ... today confirmed that the Advisory Committee for Reproductive Health ... is scheduled to review Columbia,s New Drug Application (NDA) ... of preterm birth in women with short uterine cervical ...
... Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) ... been named to the role of Executive Vice President ... employment with Valeant, which is expected to be December ... Sachs where he was the chief operating officer for ...
Cached Medicine Technology:Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA 2Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA 3Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA 4Valeant Pharmaceuticals Appoints Howard B. Schiller as Chief Financial Officer 2Valeant Pharmaceuticals Appoints Howard B. Schiller as Chief Financial Officer 3
(Date:5/26/2015)... (PRWEB) May 26, 2015 Many ... added to TheCelebrityDresses.com's formal dress collections recently. Now, ... newly designed dresses, up to 70% off. The ... the world to save hundreds of dollars on ... well-known brand in red carpet fashion special occasion ...
(Date:5/26/2015)... U.S. Food and Drug Administration (FDA) ... are extensive and can be difficult to understand. ... device companies comply with FDA regulations, compiled a list ... FDA requirements. , 1. Start researching early. ... be a lengthy process depending on the classification of ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 Carl W. ... Pinehurst Surgical Center in Pinehurst, N.C. have launched a ... surgery patients about chronic sinusitis and the benefits of ... can be used to determine if someone is a ... about symptoms and other factors that can contribute to ...
(Date:5/25/2015)... (PRWEB) May 26, 2015 The ... Hooker as a 2015-2016 inductee into its VIP Professional ... this prestigious distinction for leadership in dentistry. NAPW is ... boasting more than 700,000 members and over 200 operating ... into this exceptional group of professional women,” said NAPW ...
(Date:5/25/2015)... May 25, 2015 World Patent Marketing, ... announces the Hidee-Hose, an undergarment patent that allays women’s ... Global Women's Hosiery industry forecasts the market to reach ... and Creative Director of World Patent Marketing , ... steering ahead and is expected to maintain its lead. ...
Breaking Medicine News(10 mins):Health News:Cocktail Dresses Inspired by Celebrities on Sale at TheCelebrityDresses.com 2Health News:FDA Medical Device Regulations: Top 10 Tips for Marketing a Device in the USA 2Health News:FDA Medical Device Regulations: Top 10 Tips for Marketing a Device in the USA 3Health News:FDA Medical Device Regulations: Top 10 Tips for Marketing a Device in the USA 4Health News:Pinehurst Surgical Sinus Center Launches Pinehurst Balloon Sinuplasty Website 2Health News:National Association of Professional Women Inducts Dr. Laquinas Hooked, D.D.S. of General Dentist, Into its VIP Professional Woman of the Year Circle 2Health News:For The Courtesy Of Women's Health And Looks - World Patent Marketing Presents A New Undergarment Patent 2Health News:For The Courtesy Of Women's Health And Looks - World Patent Marketing Presents A New Undergarment Patent 3
... Singapore might be prosperous. But it is also draconian. Any presumed ... ,,As the owner of a commercial fishing pond in Pasir Ris ... for breeding mosquitoes. The area is dubbed the number one dengue ... of Wednesday. ,The National Environment Agency (NEA) believes ...
... that the combined use of two minimally invasive techniquesendobronchial ... the diagnosis of peripheral lung lesions has been shown ... does not compromise patients safety. ,Multimodality ... has pushed the diagnostic yield of flexible bronchoscopic procedures ...
... unemployed Argentine Jorge as, picking up a hammer, he goes ... of Madrid. ,Elsewhere in the same hotel, ... but the hotel manager doesn't bat an eyelid. ... the NH Hoteles chain hatched to kill two birds with ...
... from the National Cancer Institute identified Variations in two ... factor for developing lung cancer. The effect of ... that the inflammatory response is important in modulating the ... of the American Association for Cancer Research, is the ...
... found that a variation in two genes related to inflammation, ... ,The study was conducted by a team of researchers led ... University of Texas M. D. Anderson Cancer Center. ... related to inflammation between more than 1,500 lung cancer patients ...
... suicidal thoughts and behaviors appear to be associated ... medication prescriptions among children and adolescents covered by ... are frequently used to treat depression among children ... an increased risk of suicidal thinking and behavior ...
Cached Medicine News:Health News:Dengue Surge in Singapore, Man Prosecuted for Breeding Mosquitoes 2Health News:Combination of Bronchoscopic Techniques is Very Effective for Lung Lesions 2Health News:Smashing Times for Stressed Spaniards 2Health News:Gene Variation Increases the Risk of Lung Cancer 2Health News:Variation in Genes Related to Inflammation Increase Lung Cancer Risk 2Health News:Reduction in Antidepressant Leads to Suicidal Risks 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: